January 23, 2023 C-Path and Mobilise-D Collaborate to Improve Impact on the Organizations’ Common Goals Critical Path Institute is pleased to announce the recent collaboration agreement between C-Path and Mobilise-D. By
January 5, 2023 Using Real World Data from CURE ID to Identify Drug Repurposing Opportunities in Mycology: Impact of Climate Change
December 27, 2022 Polycystic Kidney Disease Development: A Conference Report Autosomal dominant polycystic kidney disease (ADPKD) is part of a spectrum of inherited diseases that also includes autosomal
December 20, 2022 C-Path’s Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox Scoring System The iBox Scoring System is available for use in kidney transplant clinical trials as a novel secondary endpoint prognostic for all
December 20, 2022 C-Path Receives Letter of Support from EMA for Parkinson’s Disease Clinical Trial Simulation Platform TUCSON, Ariz., Dec. 20, 2022 — Critical Path Institute (C-Path) today announced that the European Medicines Agency (EMA) has iss
December 16, 2022 Quantitative Study Findings: Comparability of a Provisioned Device Versus Bring Your Own Device…
December 16, 2022 eCOA Consortium and PRO Consortium Announce Publication of Two Open Access Articles C-Path’s eCOA Consortium and PRO Consortium are pleased to announce the publication of two open access articles in the Jour
December 16, 2022 Qualitative Interview Findings: Comparability of a Provisioned Device Versus Bring Your Own Device…
December 14, 2022 View Now | Shared Stewardship in Collaborative Curation of Rare Disease Datasets Patient data is a key asset in understanding the progression of rare diseases and may it be provided in a variety of forms from a
